一種新型導管裝置被用于微創冷凍治療心率不齊。這種裝置叫做Freezor Max，已經獲得勒美國食品藥品管理局的許可。

根據批準的治療指征，Freezor Max被用于心臟外表面（心外膜）以及內表面（心內膜）的治療。通過設備的尖端輸送-80度的低溫到心外膜和內膜產生局灶性損傷。這種特性使得可以產生更大或者更深的損傷，用以治療心率不齊例如室性心動過速附加旁路、心房撲動以及心房顫動。

Freezor Max還在接受評估做為治療陣發性心房撲動工具包的一部分。在這個方案中，它被用于雙向阻斷心房撲動，這是一種用于治療房撲的可接受的方法。Freezor Max是CryoCath技術集團的產品。

美國克利夫蘭診所心臟中心電生理和起搏分部主任Patrick Tchou醫生說：“ 沒有廣泛認可的方案來安全地消融流行率較高的心率不齊例如室性心動過速，尤其是起源于靠近心臟關鍵部位比如冠狀動脈血管。早期使用冷凍療法來治療這種心率不齊是令人鼓舞的；而能夠達到這些心臟關鍵部位的更有效設備，具有廣泛的臨床應用前景。”
 
Cryotherapy Catheter for Treating Arrhythmias
 
A new catheter device is used in minimally invasive cryotherapy for cardiac arrhythmias. The device, called Freezor Max, has been cleared by the U.S. Food and Drug Administration (FDA).

For the approved indication, Freezor Max is used to make lesions on the outside (epicardial) surface of the heart as well as the inside (endocardial) surface. Then it is used to create a focal lesion on the epicardium or endocardium by delivering temperatures as low as -80oC at its tip. The ability to make larger or deeper lesions is well suited to treat arrhythmias such as ventricular tachycardia (VT) accessory pathways, atrial flutter, and atrial fibrillation (AF).

Freezor Max is also undergoing evaluation as part of the toolbox approach for the treatment of paroxysmal atrial fibrillation. In this protocol, it is used to create a bi-directional block of the cavotricuspid isthmus, which is the commonly accepted method for the treatment of atrial flutter. Freezor Max is the product of CryoCath Technologies, Inc. (Montreal, Canada).

“There is no widely accepted procedure to safely ablate highly prevalent arrhythmias like VT, particularly when they originate near critical structures in the heart such as coronary blood vessels,” said Dr. Patrick Tchou, M.D., section head, electrophysiology & pacing, Cleveland Clinic Heart Center (OH, USA). “The early use of cryoablation to treat such arrhythmias has been very encouraging and a more powerful device to reach these difficult-to-reach locations in the heart has broad clinical utility.”